A detailed history of Versant Capital Management, Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 346 shares of SAGE stock, worth $1,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares
346
Previous 87 297.7%
Holding current value
$1,698
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$7.02 - $13.08 $1,818 - $3,387
259 Added 297.7%
346 $2,000
Q2 2024

Jul 05, 2024

BUY
$10.58 - $17.9 $603 - $1,020
57 Added 190.0%
87 $0
Q4 2023

Jan 08, 2024

BUY
$17.1 - $22.26 $376 - $489
22 Added 275.0%
30 $0
Q3 2023

Oct 11, 2023

SELL
$16.75 - $48.98 $117 - $342
-7 Reduced 46.67%
8 $0
Q2 2023

Jul 10, 2023

BUY
$40.65 - $59.54 $609 - $893
15 New
15 $0

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $292M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.